P
EBS icon

&Partners’s Emergent Biosolutions EBS Stock Holding History

&Partners’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$148K Buy
17,716
+275
+2% +$2.3K ﹤0.01% 2428
2026
Q1 		$145K Buy
17,441
+441
+3% +$4.57K ﹤0.01% 2296
2025
Q4 		$210K Buy
+17,000
New +$182K ﹤0.01% 2120

Other funds holding EBS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
OHA
Oak Hill Advisors New York $701M AUM 78.4% 1-Year Est. Return

&Partners's EBS Position: Q2 2026 in Review

&Partners increased its Emergent Biosolutions (EBS) stake by 1.6% in Q2 2026, buying an estimated $2.3K and bringing the position to 17,716 shares worth $148K. The position accounts for ﹤0.01% of the portfolio, ranked #2428.

&Partners first reported a position in EBS in Q4 2025 and has held it in 3 quarters since. The position peaked at $210K in Q4 2025. 195 funds tracked by Wall St. Rank hold EBS as of Q2 2026.

  • &Partners held 17,716 shares of Emergent Biosolutions worth $148K as of Q2 2026.
  • &Partners bought 275 Emergent Biosolutions shares in Q2 2026, an estimated $2.3K.
  • Emergent Biosolutions made up ﹤0.01% of &Partners's portfolio in Q2 2026, its #2428 holding.
  • &Partners first reported a position in Emergent Biosolutions in Q4 2025 and has held it in 3 quarters since.
  • &Partners's Emergent Biosolutions position peaked at $210K in Q4 2025.
  • 195 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2026.

Based on &Partners's 13F filing for Q2 2026, filed 14 Aug 2026.